Phase-separated stress granules and processing bodies are compromised in Myotonic Dystrophy Type 1
S. Gulyurtlu, M. S. Magon, P. Guest, P. P. Papavasiliou, A. R. Prescott, J. E. Sleeman
Abstract
RNA regulation in mammalian cells requires complex physical compartmentalisation using structures thought to be formed by liquid-liquid phase separation. Disruption of these structures is implicated in numerous degenerative diseases. Myotonic Dystrophy Type 1 (DM1) is a multi-systemic trinucleotide repeat disorder resulting from a CTG expansion in the dystonia myotonica protein kinase gene (DMPK). The cellular hall-mark of DM1 is the formation of nuclear foci containing expanded DMPK RNA (CUGexp). We report here the deregulation of stress granules and processing bodies (P-bodies), two cytoplasmic structures key for mRNA regulation, in cell culture models of DM1. Alterations to the rates of formation and dispersal of stress granules suggest an altered ability to respond to stress associated with DM1, while changes to the structure and dynamics of stress granules and P-bodies suggest that a more widespread alteration to the biophysical properties of cellular structures may be a consequence of the presence of CUGexp RNA.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Regulation of Toxic RNA Foci and Repeat Expansion DMPK Transcripts: Role of MBNL Proteins and RNA Decay Pathways
Xiaomeng Xing, Róbert Márkus, … J. David Brook·bioRxiv·Sep 28, 2023
- Dysregulation of circular RNAs in myotonic dystrophy type 1
Christine Voellenkle, Alessandra Perfetti, … Fabio Martelli·International Journal of Molecular SciencesPeer-reviewed·Apr 19, 2019
- Characterisation of DMPK and MBNL1 expression in cell models of Myotonic Dystrophy: A platform for drug screening
Andrea López‐Martínez, Sergio Martín‐González, … Virginia Arechavala‐Gomeza·NAR Molecular MedicinePeer-reviewed·Jun 20, 2025
- Targeting Toxic Nuclear RNA Foci with CRISPR-Cas13 to Treat Myotonic Dystrophy
Pornthida Poosala, Sean R. Lindley, … Douglas M. Anderson·bioRxiv·Jul 26, 2019
- Deregulations of miR-1 and its target Multiplexin promote dilated cardiomyopathy associated with myotonic dystrophy type 1
Anissa Souidi, Masayuki Nakamori, … Krzysztof Jagla·EMBO ReportsPeer-reviewed·Feb 28, 2023
- Transcriptome Alterations in Myotonic Dystrophy Frontal Cortex
Brittney A. Otero, Kiril Poukalov, … Eric T. Wang·Cell ReportsPeer-reviewed·Jan 1, 2021